Aardvark Therapeutics has provided new details on the safety concerns that led to the pause of a global clinical trial of ARD-101, its experimental treatment for hyperphagia, or persistent, insatiable hunger, in people with Prader-Willi syndrome (PWS). In a company press release announcing financial results and the…